Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442779 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01442779 is a Phase 2 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 18 participants.
The verdict
NCT01442779, a Phase 2 study, has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
Interventions
- DRUG Interferon alpha oral lozenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2000-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442779
The ClinicalTrials.gov registry entry for NCT01442779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha oral lozenge is the first listed.
NCT01442779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442779 about?
NCT01442779 is a clinical study titled "Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
What is the current status of trial NCT01442779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2000-09. Estimated completion is 2007-05.
What interventions are being tested in trial NCT01442779?
The interventions under investigation include: Interferon alpha oral lozenge (DRUG).
Who is sponsoring clinical trial NCT01442779?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.